display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
mBC-Triple negative (TNBC) - 2nd Line (L2)mBC - TNBC - L2 - all population
poly ADP-ribose polymerase (PARP) inhibitor
olaparib OlympiAD
talazoparib EMBRACA

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons